Sponsored by
News
Prioritise in vitro diagnostics to accelerate NHS and economic recovery, says coalition
A new report has shown that the UK can build a more preventative, efficient, and resilient healthcare system fit for the future by prioritising investment in in vitro diagnostics (IVDs) across the NHS. The Power of Testing report, developed by Roche Diagnostics in partnership with the Institute of Biomedical Science, and supported by the Royal College of Pathologists and the Association for Laboratory Medicine, builds on the ambitions set out in the Government’s recent 10-Year Health Plan for the NHS to demonstrate the urgent need to better utilise IVDs in order to unlock transformational change that will guarantee the sustainability of the service for generations to come.
Diagnostics have an essential role in patient
care delivery, but they are continually overlooked in planning and investment; while IVDs help guide over 70% of clinical decisions, they receive less than 1% of NHS budget allocation. Given the part IVDs can play in getting the right care to patients efficiently, the report shows how sufficient funding for IVDs will be crucial for realising the 10-Year Health Plan’s ambition to shift healthcare to a more preventative, personalised, and community-based model, as well as supporting system efficiency and economic productivity. The report also highlights how the expertise of the biomedical workforce should be harnessed to lead on pathway redesign and coordination of IVD adoption across the NHS, drawing on their
experience of translating innovation into safe and effective clinical practice. The report’s authors call for the Government and NHS system leaders to: l Mandate equitable funding for diagnostics, including a roadmap setting out how mandated funding can be scaled up with the biomedical workforce leading in pathway redesign to ensure efficiency and equity.
l Invest in the biomedical workforce, recognising the pivotal role of the biomedical workforce in integrating IVDs into clinical pathways by investing in their training, advanced roles, and system leadership to ensure the safe and effective deployment of diagnostic innovations
l Utilise expertise and infrastructure to support the adoption of innovation across the NHS, with
a cross-sector working group of stakeholders collaborating on implementation.
l Champion the role of non-imaging diagnostics, raising awareness of the impact of IVDs on care through key organisations, such as the IBMS, who already work to champion the importance of the sector.
The report spotlights key examples of NHS Trusts which have implemented innovative diagnostic pathways using IVDs. These include the use of the Sterilab Combi Antigen Lateral Flow Test for Flu A/ Flu B/RSV and COVID in Yorkshire and the Humber, which helped to inform rapid clinical intervention for infection prevention and bed management teams, and the roll-out of heart health screening programmes across the UK, which used NT-proBNP testing to reduce the waiting times for heart failure diagnosis from days to just 60 minutes. Geoff Twist, MD at Roche Diagnostics UK and
Ireland, said: “The report’s findings are clear: despite the huge value of IVDs, they remain overlooked as vital tools to tackle many of the NHS’s pressing challenges. Embracing IVDs as tools to detect disease earlier and support targeted treatments will lead to improved health outcomes, faster recoveries, and enable more people to engage in meaningful work – strengthening the economy, while reducing healthcare and welfare costs.” To download the report, visit:
https://www.ibms. org/resource/
the-power-of-testing-report.html
October 2025 I
www.clinicalservicesjournal.com 13
Sodel Vladyslav -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
